COVID-19

Pic:getty/richarddrury

mRNA and beyond: Opportunities for US biologics

By Staff reporter

The success of mRNA vaccine technology could be one of the new opportunities for US pharmaceutical manufacturing looking forward, with pandemic investments helping turbocharge the sector.

© GettyImages/FlashMovie

NPD Gallery: Technology Insider

By Jane Byrne

We report on some of the latest biopharma industry targeted new releases in terms of technological innovation.

© GettyImages/Urupong

Dispatches from Bio Digital 2021

Pfizer CEO: ‘There is renewed hope and trust in science’

By Jane Byrne

A lesson learnt from the COVID-19 pandemic was that human ingenuity prevailed and resolved an issue that challenged the world; the crisis also reinforced faith in the power of science, said Dr Albert Bourla, CEO of Pfizer, in a keynote interview during...

© GettyImages/Fokusiert

Moderna starts process to obtain BLA for Covid-19 shot

By Jane Byrne

Moderna has initiated the rolling submission process with the US Food and Drug Administration (FDA) for a Biologics License Application (BLA) to distribute and market its mRNA COVID-19 vaccine in the US for use in individuals aged 18 and older.